Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose

Vaccine. 2012 Apr 19;30(19):3026-33. doi: 10.1016/j.vaccine.2011.10.092. Epub 2011 Nov 7.

Abstract

Live-attenuated influenza vaccine (LAIV) is delivered to vaccine recipients using a nasal spray syringe. LAIV delivered by this method is immunogenic at current doses; however, improvements in nasal delivery might allow for significant dose reduction. We investigated LAIV vaccination in ferrets using a high efficiency nebulizer designed for nasal delivery. LAIV nasal aerosol elicited high levels of serum neutralizing antibodies and protected ferrets from homologous virus challenge at conventional (10(7)TCID(50)) and significantly reduced (10(3)TCID(50)) doses. Aerosol LAIV also provided a significant level of subtype-specific cross-protection. These results demonstrate the dose-sparing potential of nebulizer-based nasal aerosol LAIV delivery.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Intranasal
  • Aerosols
  • Animals
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood
  • Cross Protection
  • Disease Models, Animal
  • Ferrets
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / immunology*
  • Male
  • Nebulizers and Vaporizers*
  • Orthomyxoviridae Infections / prevention & control*

Substances

  • Aerosols
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Influenza Vaccines